Deborah F. Aghib, PhD

Doctor Aghib’s passion lies in healthcare and advanced technologies, where she has successfully implemented complex strategic and financial decision-making processes.  She possesses a profound understanding of scientific intricacies. She is passionate about bridging the gap between cutting-edge scientific advancements and practical, impactful solutions.

She has 27 years of executive experience, broad scientific knowledge, and significant international experience in developing long-term strategies for business development, licensing, assets spinoffs, and mergers and acquisitions in the therapeutics, medical devices, companion diagnostics, platform technologies, analytical instrument fields, telemedicine, and AI and data intensive-driven technologies.

Dr. Aghib is formerly the Managing Director of the boutique investment bank Cassel Salpeter, LLC. Dr. Aghib serves on the Board of Sequella, Inc., a clinical stage anti-infective biotech company working to bring life sparing therapy for tuberculosis to the global population; a Scientific Advisory Board member of Incyte Heath, a multidiscipline, high complexity, clinical laboratory helping revolutionize clinical decision making, improving patients lives.  Dr. Aghib was an Independent Director on the Stellar Biotechnology Board of Directors (formerly Nasdaq:SBOT), and a member of its Strategic Investment, M&A, Audit, and Corporate Governance committees.

Agent for Social Change: In addition to serving as a founding board member of The 90~10 Institute, Dr. Aghib serves as a Board Member of the non-profit OpenWorm Foundation, an open source community dedicated to integrative biological simulation of the first digital life form; a Board Member and on the financial committee of the non-profit San Francisco Art and Film for teenagers, dedicated to making over 100 first-rate cultural events available free to Bay Area students every year. 

Dr. Aghib holds a Ph.D. in Molecular and Cellular Biology from the University of Milan (Italy) and a Ph.D. in Human Genetics from the University of Pavia (Italy), and an Advanced Post-Graduate Course in Industry 4.0: Innovation, Artificial Intelligence and Robotics from the University S. Anna, Pisa (Italy).